

Developmental Therapeutics Program

NSC: 763874 / 1

Conc: 1.00E-5 Molar

Test Date: Feb 27, 2012

One Dose Mean Graph

Experiment ID: 1202OS23

Report Date: Oct 10, 2012

Panel/Cell Line

Growth Percent

Mean Growth Percent - Growth Percent

Leukemia	
CCRF-CEM	95.50
HL-60(TB)	94.30
K-562	101.03
MOLT-4	98.77
RPMI-8226	96.23
SR	109.16
Non-Small Cell Lung Cancer	
A549/ATCC	98.23
EKVX	106.29
HOP-62	105.88
HOP-92	92.09
NCI-H23	100.01
NCI-H322M	101.52
NCI-H460	107.03
NCI-H522	89.43
Colon Cancer	
COLO 205	99.77
HCC-2998	108.06
HCT-116	123.45
HCT-15	107.94
HT29	99.83
KM12	105.89
SW-620	106.70
CNS Cancer	
SF-268	107.70
SF-295	93.34
SF-539	102.35
SNB-19	104.44
SNB-75	88.88
U251	104.59
Melanoma	
LOX IMVI	99.06
MALME-3M	92.81
M14	129.63
MDA-MB-435	103.17
SK-MEL-2	98.21
SK-MEL-28	100.52
UACC-257	99.43
UACC-62	105.77
Ovarian Cancer	
IGROV1	109.60
OVCAR-3	109.10
OVCAR-4	104.91
OVCAR-5	107.29
OVCAR-8	104.00
NCI/ADR-RES	112.84
SK-OV-3	98.85
Renal Cancer	
786-0	118.49
A498	81.43
ACHN	104.58
CAKI-1	97.50
RXF 393	98.68
SN12C	105.93
TK-10	98.47
UO-31	87.86
Prostate Cancer	
PC-3	95.96
DU-145	116.54
Breast Cancer	
MCF7	87.48
MDA-MB-231/ATCC	110.22
HS 578T	96.52
BT-549	121.30
T-47D	102.28
MDA-MB-468	97.09
Mean	102.48
Delta	21.05
Range	48.20

